Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Blonanserin Augmentation for Treatment-Resistant Somatic Symptom Disorder: A Case Series

Nagoshi, Yasuhide MD, PhD; Tominaga, Toshiyuki MD, PhD; Fukui, Kenji MD, PhD

doi: 10.1097/WNF.0000000000000134
Case Reports
Buy

The augmentation of selective serotonin reuptake inhibitors with antipsychotics that have a high dopamine-receptor‐D2 affinity may be effective in treatment-resistant obsessive–compulsive disorder and somatic symptom disorder, which is similar to illness anxiety disorder. Blonanserin, a novel antipsychotic developed in Japan, has a high affinity for the D2 receptor and weak or very little affinity for other receptors. This article presents two case studies that demonstrate the efficacy of blonanserin augmentation for treatment-resistant somatic symptom disorder. Two patients with treatment-resistant somatic symptom disorder were prescribed concomitant use of blonanserin. Augmentation with blonanserin resulted in the remarkable amelioration of all symptoms. Sedative adverse drug reactions produced by aripiprazole were improved after replacing it with blonanserin. Blonanserin is effective in treatment-resistant somatic symptom disorder. Furthermore, compared with aripiprazole, blonanserin is more likely to result in medication adherence in patients with somatic symptom disorder because it reduced adverse drug reactions.

*Department of Psychiatry (Psychosomatic Medicine), Kyoto First Red Cross Hospital; and †Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Address correspondence and reprint requests to Yasuhide Nagoshi, MD, PhD, Department of Psychiatry (Psychosomatic Medicine), Kyoto First Red Cross Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto-shi, Kyoto 605-0981, Japan; E-mail: pandasportiva@yahoo.co.jp

Conflicts of Interest and Source of Funding: This study did not receive any financial or material support. The authors have no conflicts of interest to declare.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.